|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020964,
umls-concept:C0027651,
umls-concept:C0033684,
umls-concept:C0042210,
umls-concept:C0085358,
umls-concept:C0205263,
umls-concept:C0536940,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1413787,
umls-concept:C1522673,
umls-concept:C1529741,
umls-concept:C1545588,
umls-concept:C1704858,
umls-concept:C1706438,
umls-concept:C2698600,
umls-concept:C2825965
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-4-22
|
|
pubmed:abstractText |
NY-ESO-1 is a 180 amino-acid human tumor antigen expressed by many different tumor types and belongs to the family of "cancer-testis" antigens. In humans, NY-ESO-1 is one of the most immunogenic tumor antigens and NY-ESO-1 peptides have been shown to induce NY-ESO-1-specific CD8(+) CTLs capable of altering the natural course of NY-ESO-1-expressing tumors in cancer patients. Here we describe the preclinical immunogenicity and efficacy of NY-ESO-1 protein formulated with the ISCOMATRIX adjuvant (NY-ESO-1 vaccine). In vitro, the NY-ESO-1 vaccine was readily taken up by human monocyte-derived dendritic cells, and on maturation, these human monocyte-derived dendritic cells efficiently cross-presented HLA-A2-restricted epitopes to NY-ESO-1-specific CD8(+) T cells. In addition, epitopes of NY-ESO-1 protein were also presented on MHC class II molecules to NY-ESO-1-specific CD4(+) T cells. The NY-ESO-1 vaccine induced strong NY-ESO-1-specific IFN-gamma and IgG2a responses in C57BL/6 mice. Furthermore, the NY-ESO-1 vaccine induced NY-ESO-1-specific CD8(+) CTLs in HLA-A2 transgenic mice that were capable of lysing human HLA-A2(+) NY-ESO-1(+) tumor cells. Finally, C57BL/6 mice, immunized with the NY-ESO-1 vaccine, were protected against challenge with a B16 melanoma cell line expressing NY-ESO-1. These data illustrate that the NY-ESO-1 vaccine represents a potent therapeutic anticancer vaccine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD4,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CTAG1B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:CebonJonathanJ,
pubmed-author:ChenQiyuanQ,
pubmed-author:ChenWeisanW,
pubmed-author:DraneDebbie PDP,
pubmed-author:GreenSimonS,
pubmed-author:LeThuy T TTT,
pubmed-author:LemonnierFrancois AFA,
pubmed-author:LuftThomasT,
pubmed-author:MaraskovskyEugeneE,
pubmed-author:MastermanKelly-AnneKA,
pubmed-author:MateoLuisL,
pubmed-author:PearseMartin JMJ,
pubmed-author:SchnurrMaxM,
pubmed-author:SjölanderAndersA,
pubmed-author:SjölanderSigridS,
pubmed-author:SuhrbierAndreasA,
pubmed-author:TaiTsin-YeeTY
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2879-90
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15102697-Adjuvants, Immunologic,
pubmed-meshheading:15102697-Animals,
pubmed-meshheading:15102697-Antigens, CD4,
pubmed-meshheading:15102697-Antigens, Neoplasm,
pubmed-meshheading:15102697-Antineoplastic Agents,
pubmed-meshheading:15102697-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15102697-Cancer Vaccines,
pubmed-meshheading:15102697-Cell Line, Tumor,
pubmed-meshheading:15102697-Disease Progression,
pubmed-meshheading:15102697-Dose-Response Relationship, Drug,
pubmed-meshheading:15102697-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15102697-Epitopes,
pubmed-meshheading:15102697-Escherichia coli,
pubmed-meshheading:15102697-HLA-A2 Antigen,
pubmed-meshheading:15102697-Immunity, Cellular,
pubmed-meshheading:15102697-Immunoglobulin G,
pubmed-meshheading:15102697-Immunohistochemistry,
pubmed-meshheading:15102697-Melanoma, Experimental,
pubmed-meshheading:15102697-Membrane Proteins,
pubmed-meshheading:15102697-Mice,
pubmed-meshheading:15102697-Mice, Inbred BALB C,
pubmed-meshheading:15102697-Mice, Inbred C57BL,
pubmed-meshheading:15102697-Mice, Transgenic,
pubmed-meshheading:15102697-Monocytes,
pubmed-meshheading:15102697-Peptides,
pubmed-meshheading:15102697-Phenotype,
pubmed-meshheading:15102697-Plasmids,
pubmed-meshheading:15102697-RNA, Messenger,
pubmed-meshheading:15102697-Recombinant Proteins,
pubmed-meshheading:15102697-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15102697-Time Factors,
pubmed-meshheading:15102697-Transfection
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Melbourne, Victoria, Australia. Eugene_Marakovsky@csl.com.au
|
|
pubmed:publicationType |
Journal Article
|
